share_log

德琪醫藥-B：截至2024年12月31日止年度年度業績公告

ANTENGENE-B: ANNOUNCEMENT OF ANNUAL RESULTSFOR THE YEAR ENDED DECEMBER 31, 2024

HKEX ·  Mar 21 08:30

Summary by Moomoo AI

德琪醫藥2024年度收入達人民幣9,195萬元，同比增長36.7%，主要受益於中國內地市場銷量大幅上升，帶動該地區收入增長27.4%。儘管希維奧®（塞利尼索）於2023年12月獲納入國家醫保目錄後價格下調，仍實現強勁銷售表現。其他國家及地區收入同比增長85.7%。公司年內虧損由2023年的人民幣5.81億元大幅收窄45%至2024年的人民幣3.19億元。研發成本從2023年的人民幣4.06億元減少至2024年的人民幣2.59億元，主要得益於研發效率提升及許可費減少。銷售及分銷開支亦從人民幣1.93億元降至人民幣7,373萬元，主要因無亞太地區商業化相關里程碑付款，以及與翰森製藥合作後優化銷售團...展開全部
德琪醫藥2024年度收入達人民幣9,195萬元，同比增長36.7%，主要受益於中國內地市場銷量大幅上升，帶動該地區收入增長27.4%。儘管希維奧®（塞利尼索）於2023年12月獲納入國家醫保目錄後價格下調，仍實現強勁銷售表現。其他國家及地區收入同比增長85.7%。公司年內虧損由2023年的人民幣5.81億元大幅收窄45%至2024年的人民幣3.19億元。研發成本從2023年的人民幣4.06億元減少至2024年的人民幣2.59億元，主要得益於研發效率提升及許可費減少。銷售及分銷開支亦從人民幣1.93億元降至人民幣7,373萬元，主要因無亞太地區商業化相關里程碑付款，以及與翰森製藥合作後優化銷售團隊。公司持續推進九款臨床階段產品的開發，其中希維奧®已在中國內地、韓國等多個亞太市場獲批。2024年7月獲NMPA批准用於治療rrDLBCL新適應症，並已納入2024年國家醫保目錄。公司將繼續專注於推進核心研發計劃，通過「組合、互補」的研發策略，致力於開發全球同類首款、同類唯一及同類最優療法。
In 2024, DQ Biopharma's revenue reached 91.95 million yuan, a year-on-year increase of 36.7%, primarily benefiting from a significant surge in sales in the mainland China market, driving a 27.4% income growth in the region. Despite a price reduction following the inclusion of Xivio® (selinexor) in the national medical insurance catalog in December 2023, strong sales performance was still achieved. Revenue from Other countries and regions grew by 85.7% year-on-year.The company's annual loss narrowed significantly by 45% from 0.581 billion yuan in 2023 to 0.319 billion yuan in 2024. R&D costs decreased from 0.406 billion yuan in 2023 to 0.259 billion yuan in 2024, mainly due to improvements in R&D efficiency and reductions in licensing fees. Sales and distribution expenses also fell from 0.193 billion yuan to...Show More
In 2024, DQ Biopharma's revenue reached 91.95 million yuan, a year-on-year increase of 36.7%, primarily benefiting from a significant surge in sales in the mainland China market, driving a 27.4% income growth in the region. Despite a price reduction following the inclusion of Xivio® (selinexor) in the national medical insurance catalog in December 2023, strong sales performance was still achieved. Revenue from Other countries and regions grew by 85.7% year-on-year.The company's annual loss narrowed significantly by 45% from 0.581 billion yuan in 2023 to 0.319 billion yuan in 2024. R&D costs decreased from 0.406 billion yuan in 2023 to 0.259 billion yuan in 2024, mainly due to improvements in R&D efficiency and reductions in licensing fees. Sales and distribution expenses also fell from 0.193 billion yuan to 73.73 million yuan, primarily due to the absence of commercialization-related milestone payments in the Asia-Pacific region and optimization of the sales team after collaboration with HANSOH PHARMA.The company continues to advance the development of nine clinical stage products, among which Xivio® has been approved in multiple Asia-Pacific markets, including mainland China and South Korea. In July 2024, it was approved by NMPA for the treatment of a new indication for rrDLBCL and has been included in the 2024 national medical insurance catalog. The company will continue to focus on advancing core R&D programs, aiming to develop the first-in-class, only-in-class, and best-in-class therapies globally through a "combination, complementary" R&D strategy.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 261

Recommended

Related Stocks Related Stocks
Symbol Mini Chart Price
ZHAOKE OPHTH-B
06622
1.950
HANSOH PHARMA
03692
23.600
SANAI HEALTH GP
01889
0.310
REGENT PACIFIC
00575
0.420
EXTRAWELL PHAR
00858
0.045
Log In for the Full List
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina Show More
Can strong earnings reports drive Chinese concept stocks to continue rising?
77%
23%
Bullish
Bearish
1527 votes
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
On Tuesday, China's political leadership is convening at the Great Hall of the People in Beijing for the year's most significant event, known as the "Two Sessions." These closed-door meetings are the annual plenary sessions of both the National People's Congress and the Chinese People's Political Consultative Conference, typically held simultaneously in March. The sessions generally last for about ten days....

Statement

This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
OK